Net loss increased to $313.9M in FY 2026, with cash runway into Q1 2027 and no product revenue. RP1 BLA for advanced melanoma remains under FDA review after two CRLs; a 55% workforce reduction was implemented. Continued operations depend on regulatory approval or new financing.Original document: Re…
Net loss increased to $313.9M in FY 2026, with cash runway into Q1 2027 and no product revenue. RP1 BLA for advanced melanoma remains under FDA review after two CRLs; a 55% workforce reduction was implemented. Continued operations depend on regulatory approval or new financing.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
